Michael Comer, MD
Family Medicine · West Columbia, SCNPI 1699155119
Payments from drug & device makers
Across 93 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$248
- Abbott$158
- Novo Nordisk$146
- AstraZeneca$127
- AbbVie$115
- GSK$87
- plus $786 from 22 others
What the payments were for
- Food & beverage$1,60196%
- Education$654%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 11 | $248 |
| Abbott | 9 | $158 |
| Novo Nordisk | 9 | $146 |
| AstraZeneca | 5 | $127 |
| AbbVie | 7 | $115 |
| GSK | 6 | $87 |
| Sumitomo Pharma America, Inc. | 4 | $79 |
| Astellas Pharma US Inc | 2 | $77 |
| Pfizer | 5 | $71 |
| Boehringer Ingelheim | 3 | $52 |
| Stryker | 2 | $51 |
| Dynavax Technologies Corporation | 2 | $51 |
| Johnson & Johnson | 4 | $50 |
| Shire North American Group Inc | 4 | $48 |
| Amgen | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Inari Medical, Inc. | 2 | $31 |
| Novartis | 2 | $27 |
| Lilly USA, LLC | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Merck | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$1,666 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $104,051 |
| JardianceEmpagliflozin | 68 | $79,127 |
| EliquisApixaban | 50 | $51,079 |
| JanuviaSitagliptin Phosphate | 37 | $41,071 |
| MounjaroTirzepatide | 23 | $32,281 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $26,158 |
| MyrbetriqMirabegron | 26 | $22,770 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $16,725 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $16,263 |
| LinzessLinaclotide | 16 | $15,389 |
| XareltoRivaroxaban | 13 | $11,461 |
| VascepaIcosapent Ethyl | 13 | $8,380 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $8,160 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 181 | $4,741 |
| Gabapentin | 315 | $3,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $146 | $104,05183 claims |
| Boehringer IngelheimJardiance | $52 | $79,12768 claims |
| PfizerEliquis | $71 | $51,07950 claims |
| MerckJanuvia | $15 | $41,07137 claims |
| Lilly USA, LLCMounjaro | $25 | $32,28123 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $22,77026 claims |
| GSKTrelegy Ellipta | $87 | $16,26323 claims |
| AbbVieLinzess | $115 | $15,38916 claims |
| Johnson & JohnsonXarelto | $50 | $11,46113 claims |
| AstraZenecaSymbicort | $127 | $3,65113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in West Columbia
- Robert PallayWest Columbia$79K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.